Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen, Proctor & Gamble Pharma Extend RNAi Pact Through 2006

This article corrects an earlier version that contained inaccurate information. The original said the agreement runs through 2008.

 

NEW YORK, Nov. 2 (GenomeWeb News) - Invitrogen and Proctor & Gamble Pharmaceuticals have extended a research service agreement through 2006, the firms said today.

 

The agreement extends a collaboration between the two companies that is several years old.

 

According to Invitrogen's CEO Greg Lucier, P&GP has been using Invitrogen's RNAi tools such as Stealth, RNAi Gateway, and lentiviral vectors in its target-identification and -validation programs.

 

Financial details were not discussed.